Indications: ANDEMBRY is an activated Factor XII (FXIIa) inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older.
ANDEMBRY®
Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.
Product Information
Contraindications: None
Dosing:
-
Recommended dosage: initial loading dose of 400 mg (two injections of 200 mg) administered subcutaneously on the first day of treatment followed by a maintenance dose of 200 mg administered subcutaneously every month.
Administration: For subcutaneous use only.
ANDEMBRY is intended for self-administration or administration by a caregiver. Prior to treatment initiation, train patients/caregivers on proper preparation and subcutaneous (SC) administration technique of ANDEMBRY [see Instructions for Use].
Prior to administration, remove ANDEMBRY from the refrigerator and allow to sit for 30 minutes at room temperature before use.
Inspect ANDEMBRY visually for particulate matter and discoloration prior to administration, whenever solution and container permit. ANDEMBRY is a slightly opalescent to clear, brownish-yellow to yellow solution.
Administer ANDEMBRY subcutaneously into the thigh or abdomen ensuring to stay 1 inch (2 cm) away from the navel. The upper arm can also be used if a caregiver administers the subcutaneous injection.
Discard the used ANDEMBRY into a sharps disposal container (closed puncture-resistant container).
